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Abstract
Background: INI1/hSNF5 is a cellular protein that directly interacts with HIV-1 integrase (IN). It
is specifically incorporated into HIV-1 virions. A dominant negative mutant derived from INI1
inhibits HIV-1 replication. Recent studies indicate that INI1 is associated with pre-integration and
reverse transcription complexes that are formed upon viral entry into the target cells. INI1 also is
a tumor suppressor, biallelically deleted/mutated in malignant rhabdoid tumors. We have utilized
cell lines derived from the rhabdoid tumors, MON and STA-WT1, that harbor either null or
truncating mutations of INI1 respectively, to assess the effect of INI1 on HIV-1 replication.
Results: We found that while HIV-1 virions produced in 293T cells efficiently transduced MON
and STA-WT1 cells, HIV-1 particle production was severely reduced in both of these cells.
Reintroduction of INI1 into MON and STA-WT1 significantly enhanced the particle production in
both cell lines. HIV-1 particles produced in MON cells were reduced for infectivity, while those
produced in STA-WT1 were not. Further analysis indicated the presence of INI1 in those virions
produced from STA-WT1 but not from those produced from MON cells. HIV-1 produced in MON
cells were defective for synthesis of early and late reverse transcription products in the target cells.
Furthermore, virions produced in MON cells were defective for exogenous reverse transcriptase
activity carried out using exogenous template, primer and substrate.
Conclusion: Our results suggest that INI1-deficient cells exhibit reduced particle production that
can be partly enhanced by re-introduction of INI1. Infectivity of HIV-1 produced in some but not
all INI1 defective cells, is affected and this defect may correlate to the lack of INI1 and/or some
other proteins in these virions. The block in early events of virion produced from MON cells
appears to be at the stage of reverse transcription. These studies suggest that presence of INI1 or
some other host factor in virions and reverse transcription complexes may be important for early
events of HIV-1 replication.
Background
Host-virus interactions play a dynamic role during replica-
tion of all retroviruses including HIV-1 [1]. Understand-
ing these host-virus interactions may facilitate the
development of novel anti-HIV-1 strategies and efficient
gene therapy vectors. One aspect of this host-virus inter-
play is the protein-protein interactions that exist between
the viral and cellular factors [2-4]. Several viral proteins
including Integrase (IN) exhibit protein-protein interac-
tions with the host factors. IN catalyzes the insertion of
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viral cDNA, the product of reverse transcription, into host
chromosomal DNA, by a process known as integration
[5]. This process is essential for the replication of all retro-
viruses including HIV-1, and is a major event that leads to
the development of latency [6,7]. In addition to mediat-
ing the integration reaction, IN appears to influence other
processes during viral replication. IN mutations have plei-
otropic effects and disrupt processes such as reverse tran-
scription, nuclear import of pre-integration complexes,
assembly and particle production [8-15]. Mechanistic
basis of these pleiotropic effects is unknown, and suggests
that in addition to its catalytic activity, either the intact
structure of IN or its protein-protein interactions are nec-
essary for the proper execution of various steps of HIV-1
life cycle.
Retroviral IN is expressed as a part of the Gag-Pol polypro-
tein, which is assembled into virions and is subsequently
cleaved into individual proteins during maturation [5]. IN
is carried by the virus particle into the target cells where it
remains as part of the pre-integration complexes (PICs)
formed subsequent to post-entry events of uncoating and
reverse transcription [16]. PICs are high molecular weight
nucleoprotein complexes, which in addition to retroviral
cDNA contain both viral and cellular proteins [17];
[18,19].
INI1/hSNF5 and LEDGF are two host proteins that
directly interact with IN [20,21]. INI1 was originally iso-
lated as a binding partner for IN using the yeast two-
hybrid system [20]. It directly interacts with IN in vitro and
co-immunoprecipitates with Pol polyprotein in vivo [22].
INI1 is one of the four core components of the mamma-
lian SWI/SNF complex that is involved in ATP-dependent
chromatin remodeling [23]. The function of INI1 within
this complex is not yet known, and it is thought to act as
a "scaffold" bringing several components of the complex
together [24]. Several recent studies indicate that INI1 and
SWI/SNF complex are required for Tat-mediated transacti-
vation of HIV-1 LTR [25-30]. INI1 is a 385 amino acid
nuclear protein. It contains two highly conserved
domains that are direct and imperfect repeats (Rpt) of
each other and a third, fairly conserved domain termed
homology region III (HRIII), at the C-terminus of the pro-
tein [31]. The Rpt domains of INI1 are involved in pro-
tein-protein interactions with both viral and cellular
proteins and Rpt 1 is necessary and sufficient to bind to
HIV-1 IN [31-34]. Rpt II domain of the protein contains a
nuclear export signal (NES), which is masked in the full-
length protein and is functional when the C-terminal
domain is deleted [35].
We previously have demonstrated that an ectopically
expressed dominant negative mutant of INI1, termed S6,
containing the minimal IN-interaction domain potently
inhibits HIV-1 assembly and particle production [22].
This inhibition was mediated by binding of S6 to IN
within the context of Gag-Pol. These results suggested that
the effect of dominant negative mutant of INI1 may
mimic the effect of pleiotropic IN mutants and that the
interaction of INI1 with Gag-Pol is required for efficient
assembly and particle production. We have found that
INI1 itself is specifically incorporated into HIV-1 virions
and the microvescicles are devoid of this cellular protein
[36]. Furthermore, incorporation of INI1 is restricted to
HIV-1 and it is not found in other closely related primate
lentiviruses such as HIV-2, SIV-1agm or HTLV-1 and other
onco-retroviruses such as Mo-MLV [36]. This restrictive
incorporation of INI1 into HIV-1 is correlated to the spe-
cific interaction of the protein with HIV-1 IN but not with
other retroviral integrases. Furthermore, S6, the trasn-
dominant mutant derived from INI1, did not affect the
particle production of other related primate lentiviruses
and Mo-MLV, consistent with the idea that interaction of
S6 with IN is a prerequisite for its inhibitory effect. Recent
immuno-precipitation studies indicated that INI1 is also
a part of pre-integration and reverse transcription com-
plexes [37]. A recent study using the siRNA mediated
knock-down of INI1, specifically in the target cells (but
not in the producer cells) reported that INI1 is inhibitory
to early events [38]. Another study did not find inhibitory
effect, but found that INI1 was not required, by using
siRNA analysis [27]. Interestingly, these two reports differ
in their conclusions about the role of INI1 in late events.
The first study report that INI1 knock-down in the pro-
ducer cells has no effect on subsequent infectivity of the
virions [38]. On the other hand, the second study
reported that there was inhibition of p24 production in
P4 cells in which INI1 was knocked down using siRNA,
indicating that INI1 may be required for late events [27].
Thus, the role of INI1 in late events in the producer cells
or the role of virion-associated INI1 in early events
remains unresolved.
INI1 has been demonstrated to be a tumor suppressor
biallelically altered in rhabdoid tumors, an aggressive
pediatric malignancy [39]. These alterations include either
large changes involving the deletions spanning INI1/
hSNF5, and/or subtle modifications involving point
mutations and substitutions in this gene [40-42]. The cell
lines derived from these rhabdoid tumors are INI1-defec-
tive, and hence are excellent reagents to study the effect of
lack of INI1 on HIV-1 replication. Previously we have
reported that HIV-1 particle production is reduced in
MON cells, one of the rhabdoid cell lines carrying biallelic
deletions of INI1 gene. Reduction in the particle produc-
tion could be complemented by co-expression of INI1 in
MON cells along with viral proteins [22]. However it was
not clear if the inhibition of particle production is specific
to MON cells or is observed in other rhabdoid cell lines.Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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Furthermore, the stage at which the defect in infectivity of
the virions produced in MON was unknown.
Since complete elimination of a host protein by RNA
interference is difficult and since trace amounts of host
protein may be sufficient to mediate its effect, somatic cell
genetic analysis using naturally occurring cell lines har-
boring deletion of the gene of interest is valuable. Others
and we have demonstrated that knock-out of mouse Ini1
by targeted disruption and homologous recombination is
embryonic lethal [43-46]. In addition, deletion of Ini1
appears to induce apoptosis in lymphocytes in mice [47].
On the contrary, cancer cell lines with INI1 deletion are
capable of survival presumably because of their specific
cell of origin or because of the presence of additional pro-
survival factors that overcome the effect of INI1 deletion.
Thus, these cell lines are of interest to explore the effect of
INI1 on HIV-1 replication. In this report, we have exam-
ined the effect of cellular INI1 mutations on HIV-1 repli-
cation by using two different rhabdoid cell lines, MON
and STA-WT1. Our results suggest that while HIV-1 viri-
ons produced in 293T cells were able to efficiently trans-
duce rhabdoid cells, viral replication in these cells were
affected at multiple steps including particle production
and subsequent reverse transcription in the next round of
replication. These results suggest that INI1 may influence
several steps during HIV-1 replication.
Results
Reduced particle production and reduced infectivity of 
particles produced in MON cells
We have found that INI1 is incorporated into HIV-1 viri-
ons and HIV-1 based vectors [22]. To examine the influ-
ence of either cellular INI1 present in the target cells or the
virally incorporated INI1 during HIV-1 infection, we
tested the efficacy of infecting INI1-defective rhabdoid
cells, MON and STA-WT1, by the VSVG pseudotyped viri-
ons produced in 293T cells, using GFP as the marker. We
found that HIV-1 based vectors transduced MON cells
lines as efficiently as that of the 293T control cells (data
not shown).
We next used the strategy described in Figure 1 to deter-
mine replication of HIV-1 in rhabdoid cells containing
INI1 mutations. We first used MON cells that carry bial-
lelic deletions of INI1 gene along with 293T cells. Both
cell lines were transiently transfected with three-plasmid-
based vectors containing CMV-GFP as a marker and pseu-
dotyped with VSVG envelope. Viral protein synthesis and
particle production in the cells were monitored by p24
ELISA. The HIV-1 based vectors produced in MON and
293T cells were then analyzed for their ability to infect
both cell types by utilizing GFP as reporter.
The above analysis confirmed our previous report of
greater than 10-fold reduction in the amount of particle
production in MON cells as compared to that of 293T
cells (Figure 2A). Culture supernatants from 293T and
MON cells, normalized for p24, were used to infect both
cell types, and the percentage of infection was determined
as before (Figure 2B). Results of these experiments indi-
cated that while virions produced in the 293T cells were
able to infect both 293T and MON cells, virions produced
in MON cells exhibited a drastic reduction in infectivity
on both 293T and MON cells (Figure 2B). The above
results suggested that there are two blocks to HIV-1 repli-
cation in MON cells (Figure 2C). The first block results in
10–20 fold reduction in the virus particle production in
MON, and the second block leads to reduced infectivity of
virions by about 10 to 15 fold as compared to that pro-
duced in 293T cells.
INI1/hSNF5 complements the defect in particle production 
but not the defect in infectivity
To determine if the efficiency of particle production or the
efficiency of transduction/infectivity can be comple-
mented by re-expression of INI1, we co-transfected
increasing concentrations of a plasmid expressing
Heamagglutinin (HA) tagged INI1/hSNF5, along with
constant amounts of three plasmid-based-vectors into
both MON and 293T cells. Viral protein synthesis and par-
ticle production, were monitored by P24 ELISA. Results of
these analyses indicated that there was an increase (about
3 fold, ** p = 0.05 for 293T and p = 0.024 for MON) in
the intracellular levels of p24 in both MON and 293T cells
in the presence of INI1 (Figure 3A). However, the pres-
ence of INI1 in MON cells resulted in further increase
(about 10 fold *p = 0.03) in particle production as com-
pared to that in 293T cells (p = 0.07, not significant) (Fig-
ure 3B,C). Immunoblot analysis of the producer cell
lysates indicated that comparable levels of HA-INI1 were
expressed in both cell types (Figure 3D). These results
indicate that INI1/hSNF5 is able to increase the efficiency
of particle production in MON cells, in part by increasing
the intracellular viral proteins and in part by increasing
viral release (Figure 3E). These results are consistent with
our previous report, where we indicated that with re-intro-
duction of INI1, there was increase in viral particle pro-
duction as measured by p24 and an increase in number of
infectious units [22].
Previously we measured infectivity per ml of the superna-
tant regardless of the amount of p24 present in the super-
natants in the presence or absence of INI1[22]. Here we
examined the infectivity of virions produced in the pres-
ence or absence of INI1 after normalizing the culture
supernatants for the levels of p24. The results indicated
that irrespective of the presence of INI1/hSNF5, the infec-
tivity per unit amount of p24 of virions produced in MONRetrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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Experimental Strategy used to analyze steps of HIV-1 replication in INI-deficient cells Figure 1
Experimental Strategy used to analyze steps of HIV-1 replication in INI-deficient cells. Viral vectors pCMV∆R8.2, 
pMDG and pHR'-CMV-GFP were co-transfected with or without plasmid expressing HA-INI1 into 293T cells and INI-defective 
cells. Culture supernatants and cell lysates were examined for levels of the virus particle production and infectivity of the pro-
duced virions, incorporation of viral proteins and INI1, viral protein synthesis and efficiency of processing.Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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cells remained low (about 10 fold low) as compared to
that of virions produced in 293T cells (Figure 3F and 3G).
The results were similar whether the target cells used for
transduction were 293T (Figure 3F) or MON (Figure 3G)
cells. These results suggested that re-expression of INI1 in
MON cells increased the viral particle production, as
measured by p24, and number of infectious particles, as
measured by infectivity per volume. However, the infec-
tious units produced in MON per given amount of p24
remained low. These results are consistent with the
hypothesis that there are two blocks for HIV-1 replication
in MON cells as illustrated in the Figure 2C.
IN and INI1 but not other components of SWI/SNF 
complex are required for efficient particle production
The above results suggest that INI1 has a role in late events
of HIV-1 replication. To determine if IN-INI1 interaction
is required for the increase in the viral particle production,
we tested the effect of INI1 on particle production when
IN was deleted from Gag-Pol. We surmised that if INI1
effect is indirect, then presence or absence of IN should
yield the same result of increase in particle production.
We inserted a stop codon at the beginning of IN in pCMV-
∆R8.2 plasmid to generate pCMV-∆R8.2∆IN, and co-
transfected this construct with plasmids encoding enve-
lope and transducing vector along with increasing concen-
trations of INI1/hSNF5 expression plasmid into MON
cells. Particle production was monitored as before by p24
ELISA (Figure 4A). Results of these experiments indicated
that while there was a 10–15 fold increase in particle pro-
duction in the case of wild type virus, in the absence of IN
there was no significant increase in the p24 release with
∆IN virus, suggesting that IN-INI1 interaction is necessary
for this effect.
INI1/hSNF5 is a component of the mammalian SWI/SNF
complex. To determine if other components of this com-
plex are necessary for HIV-1 particle production, we trans-
fected HIV-1 DNA into C33A and SW13 cells that are
defective for BRG1 and BRM, the ATPase components of
the SWI/SNF complex. We found that there was no defect
in p24 production in these cells as compared to that of
293T cells (Figure 4B). Thus it appears that the ATPase
components of the SWI/SNF complex, BRG1 or hBRM,
and perhaps the intact SWI/SNF complex are not required
for the efficient HIV-1 particle production. This presents
an additional evidence to suggest that INI1-induced
increase in particle production in MON cells is not due to
the increase in viral transcription, since the activation of
transcription by INI1 is dependent on the ATPase compo-
nents of the SWI/SNF complex ([33] and unpublished
data).
Analysis of particle production and infectivity in MON cells:  A Figure 2
Analysis of particle production and infectivity in 
MON cells: A. Graphic representation of p24 antigen 
release (pg/ml) in the culture supernatants of 293T (■ ) and 
MON () cells transfected with three plasmid based HIV-1 
vectors (average of 3 independent experiments). B. Graphic 
representation of infectivity of virions, normalized for p24, 
produced in either 293T (■ ), or MON (). Both 293T and 
MON cells were infected with these two sets of virions 
(average of 3 independent experiments). C. Schematic repre-
sentation of 2 blocks in HIV-1 replication in MON cells. 1st 
block exists at the level of virus particle production and the 
2nd block exists at the level of infectivity. D. Schematic repre-
sentation of a block in HIV-1 replication in STA-WT1 cells at 
the level of virus particle production.Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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INI1 complements defect in the virus particle production in the MON cells in a dose-dependent manner Figure 3
INI1 complements defect in the virus particle production in the MON cells in a dose-dependent manner. A. 
Graphic representation of intracellular p24 (pg/ml) in the 293T (■ ), and MON () cells in the presence of increasing concen-
trations of HA-INI1 (average of 3 independent experiments). B. Graphic representation of particle associated p24 (pg/ml) in 
the 293T (■ ), and MON () cells in the presence of increasing concentrations of HA-INI1 (average of 3 independent experi-
ments). C. Immunoblot analysis of concentrated virions produced in 293T and MON cells in the presence of increasing con-
centrations of INI1 using α-p24 antibody. D. Immunoblot analysis of relative amounts of transfected HA-INI1 in the producer 
cells. The upper panel was probed with α-HA and the lower panel was probed with affinity purified α-INI1 antibodies. E. 
Graphic representation of fold increase in the virus particle production (■ ) and infectivity of virions produced in MON cells 
over 293T () and MON(....) cells. (F and G). Graphic representation of % infectivity of normalized virus particles over 293T 
cells (F) and MON cells (G). Virions were produced in 293T (■ ) or MON () cells in the presence of increasing concentra-
tions of INI1 (average of 3 independent experiments).Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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IN and INI1 but not the components of the SWI/SNF complex are required for efficient HIV-1 particle production Figure 4
IN and INI1 but not the components of the SWI/SNF complex are required for efficient HIV-1 particle produc-
tion. A. IN is required for the complementation of particle production by INI1. Graphic representation of particle-associated 
p24 antigen (pg/ml) in the MON culture supernatants transfected with either ∆IN Gag-Pol (■ ) or wild type Gag-Pol () along 
with increasing concentrations of INI1 (average of 2 independent experiments). B. The ATPase components of SWI/SNF com-
plex are not required for HIV-1 particle production. Graphic representation of particle associated p24 released from SW13 
and C33A, the two BRG1 and hBRM-dificient cells and 293T cells in the absence (■ ) or presence () of transfected HA-INI1 
(average of 3 independent experiments).Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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Characterization of HIV-1 particle production in STA-WT1 
rhabdoid cell line
To determine if the reduction in particle production we
observe in MON cells is seen in other INI1-defective cell
lines, we tested the replication of HIV-1 in another rhab-
doid cell line, STA-WT1, where one of the alleles of INI1
gene is deleted and the other allele harbors a single nucle-
otide deletion (delG950), leading to the expression of a
truncated protein (∆INI1, aa 1–319). This truncated INI1
protein retains two highly conserved Rpt domains that
include the IN-binding region, and is mis-localized in the
cytoplasm [35].
As before, we used single cycle infection assays to deter-
mine the ability of STA-WT1 cells to support VSVG pseudo-
typed HIV-1 particle production. We found that particle
production was dramatically decreased in these cells
(about 100 fold) as compared to that of 293T cells (Figure
5A). This defect in virus particle production is similar to
that observed in MON cells and hence we next examined
if full length INI1 could complement this defect. Similar
to that of MON cells, there was an increase (about 3–5
fold) in intra-cellular levels of p24 in the presence of INI1
(Figure 5B). Consistent with the finding in MON cells, co-
transfection of INI1 resulted in a dose-dependent increase
in particle production. We found that the highest concen-
tration of INI1 tested resulted in about 20-fold increase in
particle production, thus leading to a significant but par-
tial complementation (Figure 5C, D). Western analysis
using α-INI1 antibodies indicated the presence of both
endogenous and transfected INI1 (Figrue 5E). Thus these
results corroborate our previous finding that presence of
full length INI1 serves to increase HIV-1 particle produc-
tion in two different cell lines.
To determine the infectivity of particles produced from
STA-WT1 cells we infected 293T cells with HIV-1 vector-
containing culture supernatants normalized for p24 lev-
els. We found that, even though the amount of particles
released in STA-WT1 in the absence of transfected full
length INI1 was lower as compared to that released from
the 293T cells, their infectivity per unit amount of p24 was
similar to or even higher than those produced in 293T
cells (Figure 5F). Thus, it appears that although there was
a definitive block in particle release, there was no block in
the infectivity of the particles produced from STA-WT1
cells (Figure 2D). These results indicated that there is a
qualitative difference in the infectivity of particles pro-
duced from two rhabdoid cells, MON and STA-WT1.
Absence of INI1/hSNF5 incorporation into the virions 
produced from MON
The above set of results presented us with an interesting
paradox. One common feature, that we observed in both
MON and STA-WT1 cells, was that particle production
was low in these cells and re-introduction of INI1
increased the particle production significantly up to 20
fold. However, while virions produced in MON cells were
defective for infection, those produced in STA-WT1 cells
were infectious. These results indicate either one of the
following possibilities. (i) INI1 in the virions is not neces-
sary for infectivity; (ii) some cellular factor, which is
present in STA-WT1 but not in MON, is necessary for
infectivity; (iii) some cellular inhibitory factor, present in
MON but absent in STA-WT1 cells, reduce the infectivity
of particles produced from MON. The main difference
between these two cell lines is the complete lack of INI1
in MON, and the presence of a truncated, cytoplasmic
form of INI1 (∆INI1, aa 1–319) in STA-WT1 cells. This
cytoplasmic fragment of INI1 retains the two Rpt domains
and is potentially available for incorporation into the vir-
ions [35]. Therefore, it is possible that the cytoplasmically
localized INI1 in STA-WT1 cells is nevertheless packaged
into the HIV-1 particles and is sufficient to mediate early
events of HIV-1 replication.
To test the above hypothesis, we prepared purified and
highly concentrated virions produced from 293T, MON
and STA-WT1 in the presence or absence of transfected
HA-INI1, treated them with subtilisin, and subjected
them to immunoblot analysis. As expected, we noticed a
band of correct molecular weight corresponding to HA-
INI1 in virions produced from 293T cells (Figure 6A).
However, the virions produced from MON cells, even in
the presence of high level of INI1, exhibited very little to
no HA-INI1 incorporation (Figure 6A, compare lane 3 to
lane 6). This lack of incorporation of INI1/hSNF5 was not
due to the lack of expression of INI1 in these cells (Figure
3D). These results indicated that virions produced in
MON cells show reduced or lack of INI1/hSNF5 incorpo-
ration into the virus. At this point we do not know the rea-
son for this lack of INI1 incorporation. Unfortunately, we
were unable to express Vpr-fusion of INI1 in MON cells as
Vpr expression itself was toxic to these cells (data not
shown).
We next examined the incorporation of INI1 into virions
in the STA-WT1 cells. Production of low amounts of viri-
ons from STA-WT1 cells in the absence of INI1 made it dif-
ficult to detect endogenous truncated INI1 in the virions
by immunoblot analysis. This is because INI1 is incorpo-
rated in a stoichiometric ratio of 2:1 IN:INI1 [36] and
there are about 50 molecules of INI1 per virions. This low
amount per virion, combined with the low titer of INI1
antibody and very low amounts of particle production,
makes it prohibitive to detect endogenous INI1 in STA-
WT1 produced virions. However, sufficient quantities of
virions were produced in the presence of HA-INI1 and
hence we concentrated these virions and subjected them
for immunoblot analysis. These results indicated that vir-Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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Analysis of HIV-1 particle production and infectivity of the virions from STA-WT1 cells Figure 5
Analysis of HIV-1 particle production and infectivity of the virions from STA-WT1 cells. A. Graphic representa-
tion of virion-associated p24 antigen (pg/ml) in the culture supernatants of 293T (■ ) and STA-WT1 () cells (average of 3 
independent experiments). B. Graphic representation of intracellular p24 (pg/ml) in the 293T (■ ), and STA-WT1 () cells in 
the presence of increasing concentrations of HA-INI1 (average of 3 independent experiments). C. Graphic representation of 
virion-associated p24 antigen (pg/ml) in the culture supernatants of 293T (■ ) and STA-WT1 () cells, co-transfected with the 
viral vectors and increasing amounts of INI1 (average of 3 independent experiments). D. The above results (B) represented as 
relative fold increase in particle production. E. Immunoblot analysis of relative amounts of transfected INI1 in 293T and STA-
WT1 producer cells (top panel), using α-INI1 antibody. The same blot was reprobed with α-tubulin antibody as a loading con-
trol (bottom panel). F. Graphic representation of the % infectivity of particles normalized for p24, produced in 293T (■ ) or 
STA-WT1 () cells.Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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Analysis of INI1 incorporation into virus particles Figure 6
Analysis of INI1 incorporation into virus particles. A. Virions produced in MON cells fail to efficiently incorporate INI1. 
Immunoblot analysis of highly concentrated and subtilisin treated virions produced from 293T and MON cells in the presence 
of increasing concentrations of INI1, using α-HA antibody (top panel) followed by α-p24 antibody (bottom panels). Bottom 
band in all the lanes of the top panel is due to nonspecific binding of the antibody. B. Virions produced in STA-WT1 cells effi-
ciently incorporate INI1. Immunoblot analysis of highly concentrated and subtilisin treated virions produced from 293T and 
STA-WT1 cells in the presence of increasing concentrations of INI1, using α-INI1 antibody (top panel) followed by α-p24 anti-
body (bottom panels).Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
Page 11 of 15
(page number not for citation purposes)
ions produced in STA-WT1 cells efficiently incorporated
HA-INI1 (Figure 6B). Lack of INI1 in virions produced
from MON and presence of INI1 in virions produced from
STA-WT1 cells, and their relative infectivity, is in support
of the hypothesis that INI1 itself or INI1 associated pro-
teins present in the virions may influence the efficiency of
infectivity of these particles.
Virions produced in MON cells exhibit defect in reverse 
transcriptase activity
We next characterized the exact stage of defect in infectiv-
ity of virions produced from the MON cells. It is unlikely
that the defect in early events was at the entry step as the
particles are pseudotyped with VSVG. Since INI1 has been
demonstrated to be present in both cytoplasmic and
nuclear reverse transcription complexes, the defect could
be at any step after the entry, including uncoating, reverse
transcription, formation of PICs, nuclear localization
and/or integration. To determine the step at which the
replication of virions produced in the MON virus is
blocked in vivo, we carried out quantitative real time PCR
to determine the amount of newly synthesized viral DNA
in infected cells. Our results indicated that while virions
produced in 293T cells exhibited the robust amount of
viral DNA synthesized due to reverse transcription, the
virions produced in MON exhibited a drastic reduction in
both early (minus strand strong stop DNA) and late (Gag)
viral DNA synthesis in the infected cells (Figure 7A).
We also tested the ability of the particles produced in
MON cells to mediate reverse transcriptase activity in vitro
using poly rA-oligo dT template-primer (Figure 7B). The
RT activity was normalized as CPM incorporated per ng of
virus associated p24. The results of these experiments
indicated that while the virions produced in 293T cells
demonstrated slightly increased RT activity in the presence
of INI1, virions produced in MON were defective for
reverse transcriptase activity (Figure 7B). These results sug-
gest that virions produced in MON cells are blocked at
reverse transcription step in the target cells.
One possibility we considered is that the virions produced
in MON may be specifically defective for incorporation of
Gag-Pol but not Gag molecules, as INI1 binds to IN, and
that the lack of Gag-Pol incorporation could explain the
lack of reverse transcriptase activity in these virions. To
test this possibility, we subjected purified and concen-
trated virions, produced in MON cells in the presence and
absence of INI1, to immunoblot analyses with antibodies
against RT, p24 and anti-HIV-1 antibodies derived from
patient serum. As expected, there was a significant
increase in the levels of p24 in the culture supernatants of
MON cells when INI1 was expressed in the producer cells.
Furthermore, the purified virions produced in these cells
demonstrated the presence of all the viral proteins,
although there were some minor differences in the par-
tially processed viral proteins (Figure 7C, D). These results
suggested that perhaps INI1 and/or other host proteins
are necessary for a step before or during the early events of
reverse transcription.
...
Discussion
In this report, we demonstrated that replication of HIV-1
is affected at multiple steps in cell lines defective for the
integrase binding host factor INI1/hSNF5. We used two
rhabdoid cell lines, MON and STA-WT1 defective for
INI1/hSNF5 gene in our studies. While MON cells harbor
complete deletion of INI1 gene, STA-WT1 cells harbor a
single point mutation in the gene resulting in the expres-
sion of a cytoplasmically localized truncated protein [35].
Our results demonstrate that rhabdoid cells are efficiently
infected by HIV-1 indicating that expression of a full
length INI1 in the target cells is not required. These results
are not surprising, as we have previously demonstrated
that INI1 is specifically incorporated into HIV-1 virions
with an IN:INI1 ratio of approximately 2:1 [36]. There-
fore, it is possible that INI1 brought into the target cells by
the virions may be sufficient to support early events of
HIV-1 replication. Furthermore, recent reports indicated
that siRNA (small interfering RNA) mediated knock-
down of INI1 in the target cells did not inhibit HIV-1
infection, or enhanced the infectivity to some degree
[27,38]. These results are consistent with our results that
MON and STA-WT1 cells are readily transduced by the
HIV-1 based vectors. Maroun et al also reported that
knock-down of INI1 in the producer cells did not affect
the infectivity. However, these later experiments need to
be further substantiated, as no data was provided in this
report that demonstrated the lack of INI1 in the virion
particles produced from the INI1 knock-down cells.
Our analysis also indicated that both MON and STA-WT1
cells exhibit reduced particle production, which is
enhanced/complemented by reintroduction of full length
INI1 into these cells. Interestingly this enhancement was
not efficient for virions deleted of IN indicating that per-
haps, binding of IN to INI1 is required for efficient parti-
cle production. Furthermore, the cell lines defective for
ATPase component of the SWI/SNF complex such as
BRG1 and BRM are not defective for particle production.
These results suggest that INI1 alone, but not the SWI/SNF
complex is required for HIV-1 particle production. It is not
clear how INI1 facilitates late events at this point. But our
results suggest that INI1 affects late events at two stages.
On the one hand it enhances the levels of viral proteins
within the rhabdoid cells and on the other hand it also
increases virus particle production. INI1 could stabilize
and direct the viral proteins into specific compartments orRetrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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Virions produced in MON cells are defective for early reverse transcription Figure 7
Virions produced in MON cells are defective for early reverse transcription. A. Graphic representation of copy 
number of early and late reverse transcription products formed upon infection of 293T cells. Equal quantities of virions pro-
duced in 293T (■ ) and MON () cells were used for infection and the copy numbers of RT products were determined by 
quantitative real time PCR. B. Reverse transcriptase activity of virions produced in 293T and MON cells. Virions collected at 
various times after transfection were concentrated and quantitated by p24 ELISA. Normalized amounts of virins were sub-
jected to reverse transcriptase analysis. The graph represents CPM incorporated per ng of p24. C. and D. Analysis of concen-
trated virion proteins produced in MON cells in the presence of INI1. Immunoblot analysis of the virions produced in 293T 
and MON cells in presence or absence of INI1, by using α-p24 (C, top panels and D, bottom panel), α-RT (C, bottom panel), 
and α-hIgG from a patient serum (D, top panel). ...Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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it may be required to overcome some host inhibitory fac-
tors that could block these events in these cells.
It is intriguing that particles produced in MON cells exhib-
ited reduction in infectivity as compared to those pro-
duced in either 293T cells or STA-WT1 cells, when
normalized for p24. Both MON and STA-WT1 cells are
rhabdoid cells and while MON cells completely lack INI1,
STA-WT1 cells possesses a truncated version of INI1.
Examination of the particles produced in these two cell
lines indicate that while INI1 was efficiently incorporated
into the particles produced in STA-WT1, it was not incor-
porated into the particles produced in MON. Thus, infec-
tivity of HIV-1 particles correlated with the ability to
incorporate INI1. These results suggested that presence of
INI1 in the producer cells and its incorporation into the
virions may enhance the particle production and infectiv-
ity of HIV-1. However, at this point we cannot rule out the
possibility that the reduced infectivity of the virions could
either be due to the lack of other INI1-associated proteins
or another host protein unrelated to INI1 in MON cells. It
remains to be determined as to what causes the block in
incorporation of INI1 into HIV-1 particles in MON cells.
It is interesting to note that the amount of particle produc-
tion is much less in STA-WT1 as compared to that of 293T
or MON cells even in the presence of high amount of
INI1. Furthermore, particles produced in STA-WT1 cells
are more infectious than those produced in 293T cells.
One possible explanation for the above observation is the
presence of truncated INI1 (∆INI1, aa 1–319) in STA-WT1
cells. This mutant retains integrase binding Rpt1 domain.
We have previously demonstrated that this truncated
mutant is localized in the cytoplasm in STA-WT1 cell lines
[35]. We believe that presence of this mutant makes it
harder for the particle release, as it acts as a dominant neg-
ative mutant, and that the wild type INI1 is able only to
partially complement this defect.
The defect in infectivity of virions produced in the MON
cells appears to be due to a block in reverse transcription
in the target cells. This block in reverse transcriptase activ-
ity was not complemented by INI1, so is infectivity and is
consistent with the lack of INI1 in the particles. These
results although unexpected, are not unprecedented.
Mutants of IN have been shown to affect reverse transcrip-
tion and this function has been ascribed to the direct
binding of IN to RT [9-11]. At this point, mutants of RT
that are solely defective for IN binding and show reduced
activity have not been isolated, to unequivocally demon-
strate that direct binding of these two proteins alone is
sufficient to modulate RT activity. Our results that lack of
INI1 in the virions make the particles defective for reverse
transcriptase activity, raises the possibility that INI1 or
another component that is missing in MON may be
required for efficient reverse transcriptase activity. The fact
that INI1 indeed is a part of the reverse transcription com-
plexes in the target cells, further lends support to the
notion that INI1 may somehow be involved in early
reverse transcription [37]. Further experiments are needed
to elucidate the mechanism by which particles produced
in MON are defective for reverse transcriptase activity.
Conclusion
Our results indicate that there is a decreased HIV-1 parti-
cle production in cell lines defective for INI1. Reintroduc-
tion of INI1 results in increase in particle production in
these cells, suggesting that INI1 in the producer cells is
necessary for efficient particle production. Furthermore,
while HIV-1 virions produced in MON cells are less infec-
tious, those produced from STA-WT1 were more infec-
tious. Analyses of the virions produced in these cells
indicate that while particles produced from MON cells
failed to incorporate INI1, those produced from 293T effi-
ciently incorporated INI1. Particles produced from MON
cells lacking INI1 were defective for carrying out early and
late reverse transcription in target cells. Furthermore,
reverse transcriptase activity of the virions produced in
MON was defective. These results suggest that defect in
INI1 or some other host function of rhabdoid cells mod-
ulate the efficiency of HIV-1 replication.
Methods
Virus particle production
293T, MON and STA-WT1 cells were co-transfected with a
total of either 10 or 20 µg of DNA containing pHR'-CMV-
GFP, pCMV-∆R8.2 and pMDG (expressing VSVG enve-
lope) in a 2:1:1 ratio respectively, using the calcium phos-
phate transfection kit (Specialty Media). For INI1
complementation studies, cells were co-transfected with
10  µg of the above plasmids along with increasing
amounts of pCGN-INI1 (expressing HA-INI1), keeping
the total amount of transfected DNA constant at 40 µg by
using pCDNA. Culture supernatants were collected from
transfected cells 48 hrs post-media change, treated with 20
U/ml of DNAseA [36], and subjected to p24 ELISA
(DuPont).
Analyzing the infectivity of virions
About 105 cells seeded in six well plates were infected by
the normalized amounts of virions, and percentage of
GFP-positive cells was determined by FACS (Fluorescent
activated cell sorter), five days post-infection. Quantita-
tion of viral proteins was determined by using p24 ELISA
using standard methods.
Subtilisin treatment of purified HIV-1 virions
Virions purified and concentrated by sucrose density gra-
dient centrifugation were treated with subtilisin as
described [36]. The treated virion pellets were resus-Retrovirology 2006, 3:56 http://www.retrovirology.com/content/3/1/56
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pended in the lysis buffer (25 mM Tris-Cl, pH 7.5, 50 mM
KCl, 0.025% Triton X-100, 50% glycerol) and mixed with
2x loading buffer (2 × = 0.25 M Tris-Cl pH 6.8, 8% SDS,
40% glycerol, 3.6% β-mercaptoethanol, 0.005%
bromophenol blue).
Antibodies
Immunoblot analyses were carried out by chemilumines-
cence methods by using the antibodies: (i) monoclonal α-
IN antibodies (hybridoma clone #8E5-1F9); (ii) affinity
purified polyclonal α-INI1 antibody, INI1-PB3 [22]; (iii)
goat polyclonal α-p24 antibody (Goat#81, Bleed #
001090); (iv) monoclonal α-Tubulin antibody (Sigma,
Catalogue # T5168); (v) polyclonal α-HA antibody (Santa
Cruz, catalogue# SC-805); (vi) patient serum containing
α- HIV-1 antibody (AIDS Reagent Program, catalogue #
3957); and (vii)monoclonal α-RT antibody (clone
8C4D7).
Quantitative Real-Time PCR
Normalized, DNase-1 treated virions were used to infect
1.0 × 105 293T cells in 6-well plates for 2 hours, then
washed with PBS, and placed into fresh DMEM for addi-
tional 4 hours. Genomic DNA was isolated at 6 hr. post-
infection using DNeasy kit (Qiagen). Early HIV-1 reverse
transcripts were quantitated using primers ert2f, ert2r and
the ERT2 probe [48]. Late HIV-1 reverse transcripts were
quantitated with primers MH531, MH532, and the probe
LRT-P [49]. Each 20 µl reaction contained 1x Taqman uni-
versal master mix (Applied Biosystems), 300 nM primers,
100 nM Probe, and 500 ng of genomic DNA. PCR condi-
tions were as described before [49]. Reactions were ana-
lyzed in triplicates using the ABI Prism 7700 sequence
detection system (Applied Biosystems).
RT assay
The virions were precipitated by adding PEG and were
subjected to RT assay as previously described using poly
rA-oligo dT template-primers and α-P32 dTTP [36].
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